TAK

TAK R&D to Revenue

15.00%Fiscal year

Period ending:

TAK FY R&D/Revenue%
TAK FY R&D/Revenue32.98%-3.53%
2000-03-312026-03-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year.

TAK r&d to revenue history

R&D spending as percentage of revenue. The available annual fiscal periods series contains 27 observations from Mar 31, 2000 to Mar 31, 2026.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
15.0015%
15.9384%
17.0886%
15.7251%
14.7404%
14.2524%
14.9517%
17.5593%
18.381%
17.9917%
19.136%
20.6849%
20.1905%
20.6338%
18.6811%
20.3521%
20.2182%
29.4504%
20.0602%
14.8104%
13.9947%
12.5964%
0%
0%
0%
0%
0%

Compare r&d to revenue

All TAK financial metrics · TAK stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.